MDCX insider filings
Medicus Pharma Ltd. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-17. Screen MDCX transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 14 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Bokhari Raza — Chief Executive Officer, Director, 10% owner | 2 | — | — | 3 |
| Bonner Carolyn F. — President and CFO | 2 | — | — | 3 |
| Brennan Edward J. — SVP, Medical Affairs | 2 | — | — | 3 |
| Mehmud Faisal — Chief Medical Officer | 2 | — | — | 3 |
| Smith Andrew Alasdair — Chief Operating Officer | 2 | — | — | 3 |
| Ciaruffoli Robert J. — Director | 1 | — | — | 1 |
| Kaiser Larry — Director | 1 | — | — | 1 |
| MAHAFFY PATRICK J — Director | 1 | — | — | 1 |
| May Sara R. — Director | 1 | — | — | 1 |
Recent insider filings — Medicus Pharma Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-17 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 14,534 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 14,534 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | May Sara R. — Director | Grant/award (A): 5,813 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 14,534 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | Kaiser Larry — Director | Grant/award (A): 14,534 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | Ciaruffoli Robert J. — Director | Grant/award (A): 72,674 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | Brennan Edward J. — SVP, Medical Affairs | Grant/award (A): 14,534 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | Bokhari Raza — Chief Executive Officer, Director, 10% owner | Grant/award (A): 436,046 @ $1.72 | EDGAR |
| 2026-11-17 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 29,069 @ $1.72 | EDGAR |
| 2026-09-08 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 2,941,176 @ $0.17 · Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 1,470,588 @ $0.17 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 588,235 @ $0.17 · Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 1,470,588 @ $0.17 · Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 735,294 @ $0.17 · Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Rodgers Cathy McMorris — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Raju Ajay — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | May Sara R. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kaiser Larry — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Ciaruffoli Robert J. — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 250,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | FISHMAN BARRY — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 500,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Ashton William — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Rodgers Cathy McMorris — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Raju Ajay — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Mehmud Faisal — Chief Medical Officer | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | May Sara R. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Kaiser Larry — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Ciaruffoli Robert J. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | FISHMAN BARRY — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Ashton William — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-04-01 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | May Sara R. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Kaiser Larry — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Ciaruffoli Robert J. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Brennan Edward J. — Chief Scientific Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Bonner Carolyn F. — President and CFO | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | FISHMAN BARRY — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Bokhari Raza — Chief Executive Officer, Director | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Ashton William — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Smith Andrew Alasdair — Chief Operating Officer | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | MAHAFFY PATRICK J — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Medicus Pharma Ltd.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-19 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 3.03 — Material Modification to Rights of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-11-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-23 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-16 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-10-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-14 | 8-K | 1.02 — Termination of a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-11 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MDCX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs